Clinical trials: Influenza, Human
Influenza
Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine
Is VAX125 safe at doses ranging from 0.1 to 8 ug when delivered i.m. in a single dose regimen Is VAX125 able to induce a post-vaccination serum HAI antibody response in healthy adults against the influenza A virus H1 HA.
- Trial name
- NCT00730457
- Testing
- VAX125
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Influenza, Influenza Immunisation
Development of Childhood Anti-Influenza Immunity
This study is a prospective surveillance of the immune response to seasonal vaccination in healthy children. The study will enroll a total of approximately 220 subjects.
- Trial name
- NCT03673345
- Testing
- Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia
The live attenuated influenza vaccine (LAIV) is made up of weakened influenza viruses given into the nose and in early studies was shown to be better than the standard influenza vaccine at preventing infections in children.
- Trial name
- NASIMMUNE (NCT02972957)
- Testing
- Nasovac-S, Azithromycin
- Where
- The Gambia
- Volunteers
- 364 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Healthy
Improving Communication During a Pandemic Flu Outbreak
During the last pandemic influenza antivirals were prescribed both as prophylaxis and treatment. However, adherence rates were suboptimal.
- Trial name
- NCT03431012
- Testing
- Agency Assignment framing, Attribute framing
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- King's College London
Influenza
A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
This is a randomized, blinded, controlled phase I clinical trial with a total of 120 participants aged ≥ 60 years. Experimental group: Influenza virus split vaccine (0.7mL/vial), control group 1: Influenza virus split vaccine…
- Trial name
- NCT07302256
- Testing
- Influenza virus split vaccine (0.7mL/vial), Influenza virus split vaccine, Phosphate buffer solution (PBS)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Influenza
Heterosubtypic Immune Responses to Influenza in Older People
Vaccination is the principal means of combating epidemic and pandemic influenza. As vaccines induce relatively strain-specific and short-lived antibody responses, annual immunisation with regularly updated vaccine is recommended…
- Trial name
- NCT00798343
- Testing
- Seasonal vaccine, H5 vaccine
- Where
- United Kingdom
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- University Hospitals, Leicester
H7N9 Subtype of Influenza A Virus
Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection
The purpose of this program is to provide pre-approval access to pimodivir for the treatment of a patient(s) with H7N9 influenza A infection.
- Trial name
- NCT03834376
- Testing
- Pimodivir
- Sponsor
- Janssen Research & Development, LLC
Pneumococcal Polysaccharide Vaccine, Influenza Vaccines
Preoperative Pneumococcal and Influenza Vaccination to Prevent Postoperative Pulmonary Infection in Patients Undergoing Lung Resection for Pulmonary Nodules or Lung Cancer
Postoperative pneumonia (POP) affects 4%-24% of lung cancer surgery patients, increasing mortality, stay, costs and worsening prognosis, especially in older patients.
- Conditions
- Pneumococcal Polysaccharide Vaccine, Influenza Vaccines, Preoperative, Lung Resection Surgery
- Trial name
- NCT07885540
- Testing
- 23-valent pneumococcal polysaccharide vaccine, Quadrivalent split-virion influenza vaccine
- Volunteers
- 1,278 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Influenza
A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age
The purpose of this study is to assess the safety and immunogenicity of different formulations of GSK Biologicals' influenza candidate vaccine GSK1557484A, in children 6-35 months of age.
- Trial name
- NCT02719743
- Testing
- Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
- Where
- 7 sites in Taiwan, Thailand
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Enterovirus 71 and Influenza Virus
Virosensor -Based Real-time Diagnosis of Enterovirus 71 and Influenza Virus
To develop a real-time diagnostic technique with Virosensor for Enterovirus 71 and Influenza Virus detection, the investigators conduct a prospective clinical study.
- Trial name
- NCT02009735
- Testing
- virosensor
- Where
- Taiwan
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Infection in Solid Organ Transplant Recipients
Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza Vaccination
Randomized, multicenter, open label trial to compare safety and efficacy of two doses stationary flu vaccination vs one doses in Solid Organ Transplant Recipients.
- Trial name
- TraNsgripe (NCT01761435)
- Testing
- Influenza vaccine
- Where
- 12 sites in Spain
- Volunteers
- 499 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Influenza
Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses. To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age.
- Trial name
- NCT00192140
- Testing
- FluMist
- Where
- 11 sites in United States
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Influenza Vaccination of HIV Infected Pregnant Women: Safety and Immunogenicity
This randomized, placebo controlled trial will evaluate the safety and immunogenicity of Trivalent Influenza Vaccine (TIV) in HIV-infected pregnant women, dynamics of transplacental anti-influenza antibody transfer to their…
- Trial name
- MatfluHIVpos (NCT01306682)
- Testing
- Trivalent influenza vaccine, Normal saline
- Where
- South Africa
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- University of Witwatersrand, South Africa
Influenza, Orthomyxoviridae Infections
Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children
This study is part of an effort to develop an effective vaccination program in children in the event of a pandemic. Study objectives: To describe the safety profiles in the periods following each vaccination in subjects receiving…
- Conditions
- Influenza, Orthomyxoviridae Infections, Orthomyxovirus Infections
- Trial name
- NCT00884182
- Testing
- A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine
- Where
- 13 sites in Finland
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Coronary Artery Diseases, Myocardial Infarction
The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases
This study wishes to understand: 1. whether vaccination against influenza in coronary artery disease (myocardial infarction and stable angina) patients is as effective as it is in healthy subjects; 2.
- Conditions
- Coronary Artery Diseases, Myocardial Infarction, Stable Angina
- Trial name
- NCT00607217
- Testing
- influenza vaccine
- Where
- Iran
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Influenza, Viral Respiratory Infection
A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections
A multicenter, randomized, double-blind, placebo controlled comparative study to evaluate the safety, tolerability and efficacy of XC221 used at 100 mg daily and at 200 mg daily in patients with uncomplicated influenza or other…
- Conditions
- Influenza, Viral Respiratory Infection, Acute Viral Upper Respiratory Infections
- Trial name
- NCT05030324
- Testing
- XC221 100 mg, XC221 200 mg
- Where
- 9 sites in Russia
- Volunteers
- 255 people
- Sponsor
- Valenta Pharm JSC
Influenza, Acute Respiratory Infection
FluSAFE: Flu SMS Alerts to Freeze Exposure
Influenza infection results in an estimated 31 million outpatient visits, 55,000 to 974,200 hospitalizations, and 3,000 to 49,000 deaths.
- Conditions
- Influenza, Acute Respiratory Infection, Influenza-like Illness
- Trial name
- NCT03274310
- Testing
- Educational text messages
- Where
- United States
- Volunteers
- 1,918 people, healthy volunteers welcome
- Sponsor
- Columbia University
Healthy, no Evidence of Disease
Cholecalciferol and Flu Vaccine in Treating Healthy Participants
This randomized clinical trial studies cholecalciferol and flu vaccine in treating healthy participants. Cholecalciferol may increase the immunologic response of flu vaccine in healthy participants.
- Trial name
- NCT01561989
- Testing
- cholecalciferol, questionnaire administration, trivalent influenza vaccine
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Vaccination; Infection
Mood and Influenza Vaccine Response: A Feasibility Trial
This study is a 2-arm, parallel, randomised controlled feasibility trial of a brief video intervention designed to induce positive affect (mood) in older adults in primary care settings prior to the receipt of influenza…
- Trial name
- NCT03144518
- Testing
- Positive Affect Intervention, Neutral Control Intervention, Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
- Where
- United Kingdom
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Influenza, Flu
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
The aim of the study was to describe the safety and immunogenicity of the 2017-2018 formulation of Fluzone Quadrivalent vaccine in children 6 months to < 9 years of age, and in adults 18 to < 65 years of age, and to describe the…
- Trial name
- NCT03308825
- Testing
- Fluzone Quadrivalent vaccine, Fluzone High-Dose vaccine
- Where
- 3 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company